OncoMatch/Clinical Trials/NCT04830267
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Is NCT04830267 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Camrelizumab for nasopharyngeal carcinoma.
Treatment: Camrelizumab — Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer. Stereotactic body radiotherapy is a potential immunostimulatory therapy that may amplify antitumor response when combined with camrelizumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
WBC ≥ 2 K/microliter; Neutrophils ≥ 1.5 K/microliter; Platelets ≥ 100 K/microliter; Hemoglobin ≥ 9.0 g/deciliter
Kidney function
Serum Creatinine ≤ 1.5 x ULN or creatinine clearance > 40ml/min using the Cockcroft-Gault formula
Liver function
AST/ALT ≤ 3 x ULN; Total bilirubin <1.5 x ULN (except subjects with Gilbert Syndrome who can have total bilirubin <3.0 mg/deciliter)
Screening laboratory values must meet the following criteria (using CTCAE v4.0): WBC ≥ 2 K/microliter Neutrophils ≥ 1.5 K/microliter Platelets ≥ 100 K/microliter Hemoglobin ≥ 9.0 g/deciliter Serum Creatinine ≤ 1.5 x ULN or creatinine clearance > 40ml/min ... AST/ALT ≤ 3 x ULN Total bilirubin <1.5 x ULN (except subjects with Gilbert Syndrome who can have total bilirubin <3.0 mg/deciliter).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify